Embracing AI in oncology: A fireside chat with industry leaders at AACR 2024 - Tempus

06/25/2024

Embracing AI in oncology: A fireside chat with industry leaders at AACR 2024

Industry leaders highlight the importance of multimodal data, AI-driven diagnostics, and the necessity of innovative approaches to meet the challenges of oncology treatment.

Authors Iker Huerga
EVP, Life Science Strategy and Real World Data, Tempus

Cristian Massacesi
Chief Medical Officer and Chief Development Officer for Oncology, AstraZeneca

<span data-mce-type="bookmark" style="display: inline-block; width: 0px; overflow: hidden; line-height: 0;" class="mce_SELRES_start"></span><span data-mce-type="bookmark" style="display: inline-block; width: 0px; overflow: hidden; line-height: 0;" class="mce_SELRES_start"></span><span data-mce-type="bookmark" style="display: inline-block; width: 0px; overflow: hidden; line-height: 0;" class="mce_SELRES_start"></span><span data-mce-type="bookmark" style="display: inline-block; width: 0px; overflow: hidden; line-height: 0;" class="mce_SELRES_start"></span><span data-mce-type="bookmark" style="display: inline-block; width: 0px; overflow: hidden; line-height: 0;" class="mce_SELRES_start"></span>

Related Content

View more

08/29/2025

Precision Medicine 2.0: The operating system for oncology R&D

This white paper addresses the persistent challenges in oncology R&D, demonstrating how precision medicine has evolved into a new paradigm built on systems-level understanding and AI-driven insights. Download for a comprehensive overview of Precision Medicine 2.0, its core scientific pillars, enabling technologies, and how R&D organizations can leverage this integrated approach to optimize their cancer research.
Read more
08/15/2025

Tempus’ data solutions for commercialization

Learn how our multimodal real-world data can help quantify new market opportunities, build your value story, and inform your market access strategy.
Read more
08/15/2025

Tempus’ data solutions for clinical development

Learn how our multimodal real-world data can help you optimize trial design, mitigate risk, and inform your companion diagnostic strategy.
Read more